Sarepta noted that patients in the study showed “continued stabilization of walking ability” on a 6-minute walk test. The study, which has compiled more than two years of data, achieved its primary endpoint during Week 48, when muscle biopsies showed increased novel dystrophin in patients taking eteplirsen. The study continues to monitor patients taking the drug to determine its long-term safety. Sarepta has now disclosed data from the study through Week 120.

The company’s CEO noted that patients taking the drug displayed “walking stability that we believe would not be expected based on the natural history of this disease over the same time period.” Sarepta noted that patients receiving the drug had not shown “significant treatment-related adverse events and no treatment-related serious adverse events.”

SRPT stock reached a high of almost $55 a share in October. But SRPT stock plunged in November after the U.S. Food and Drug Administration (FDA) said the application for eteplirsen was ”premature.”

Over the past twelve months, SRPT stock has fallen almost 20%. SRPT stock current trades over $20 a share.